and recommendation
Vericel Corporation (VCEL)
Vericel Corporation (VCEL) a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.
VCEL markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.
VCEL also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
- March 10, 2018 - 9:22am | Earnings, Earnings Q4
- March 4, 2018 - 11:11am | Analysis, Out and About
- January 2, 2018 - 9:29am | Out and About, Research Notes
- November 3, 2017 - 1:08pm | Earnings, Earnings Q3
- May 5, 2017 - 8:59am | Earnings, Earnings Q1
- March 27, 2017 - 12:52pm | Out and About, Research Notes
- March 10, 2017 - 12:00am | Earnings, Earnings Q4
- February 9, 2017 - 1:13pm | Research Notes
- December 15, 2016 - 8:37pm | Research Notes, Financings
- November 29, 2016 - 2:30pm | Research Notes
- November 2, 2016 - 8:46pm | Earnings, Earnings Q3
- September 12, 2016 - 9:05am | Research Notes
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2
- April 4, 2016 - 12:43pm | Henry'omics, Regulatory
- March 10, 2016 - 9:46am | Research Notes, Henry'omics
- March 9, 2016 - 9:03am | Henry'omics, Financings
- March 7, 2016 - 9:39am | Henry'omics, Out and About
- February 22, 2016 - 8:47am | Research Notes
- December 8, 2015 - 8:57am | Research Notes
- November 16, 2015 - 10:34am | Earnings Q3